WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Primary Biliary Cirrhosis - Pipeline Review, H1 2018”
Primary Biliary Cirrhosis (PBC) is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrates and liver transplantation.
Primary biliary cholangitis is suspected based on a medical history, physical exam, and lab tests that show high levels of the enzyme alkaline phosphatase and ant mitochondrial antibodies (AMA) in the blood.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811461-primary-biliary-cirrhosis-pipeline-review-h1-2018
Primary Biliary Cirrhosis Industry Major Highlights:
Biliary Cirrhosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The report further guide in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Primary Biliary Cirrhosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Apart from this various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Major Outlook for Primary Biliary Cirrhosis Report:
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cirrhosis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis
The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis.
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources.
Competitive Analysis for Primary Biliary Cirrhosis
Key players are making innovative developments in Primary Biliary Cirrhosis industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector.
The key players in this market are Albireo Pharma Inc, Arena Pharmaceuticals Inc, Cadila Healthcare Ltd, Dr. Falk Pharma GmbH, Gilead Sciences Inc, Novartis AG, Tiziana Life Sciences Plc and Virobay Inc
Table of Contents
Global Markets Direct Report Coverage 5
Primary Biliary Cirrhosis - Overview 6
Primary Biliary Cirrhosis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Primary Biliary Cirrhosis - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development 19
ActiveSite Pharmaceuticals Inc 19
Coherus BioSciences Inc 19
Lupin Ltd 20
Mabion SA 20
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811461-primary-biliary-cirrhosis-pipeline-review-h1-2018
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
P: +44 208 133 9349
M: +1 646 845 9349